Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified FCR Regimen in Previously Untreated Chronic Lymphocytic Leukemia
NCT00280241Phase 2Completed
- Sponsor
- University of Pittsburgh
- Start
- Jun 2004
- Primary completion
- Feb 2008
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, fludarabine, cyclophosphamide in chronic lymphocytic leukemia (CLL), sponsored by University of Pittsburgh. Started Jun 2004; status: completed.
02
Drugs
rituximabfludarabinecyclophosphamide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00280241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00280241.